This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


SK Biopharmaceuticals Co., Ltd.

Drug Names(s): Carisbamate, RWJ-333369, YKP 509, JNJ-10234094

Description: Comfyde is a monocarbamate with anticonvulsant activity. Its mechanism of action has not been elucidated.

Deal Structure: Johnson & Johnson and SK
In 1999, Johnson & Johnson licensed Comfyde from SK-Bio Pharmaceuticals. Johnson and Johnson received global marketing rights for the compound.

In May 2011, Ortho-McNeil, a subsidiary of Johnson & Johnson, returned full development and commercialization rights of carisbamate back to SK.

Comfyde News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug